Novartis files for Alcon spinoff, citing aging population and developing countries as top growth prospects

Novartis filed a registration statement with the SEC for the spinoff of its eye-care unit, Alcon. It hasn't placed a valuation on the transaction just yet, but previous CEO Joe Jimenez said last year it could be worth as much as $35 billion.